A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (NCT06208150)
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Who can join: Review the eligibility criteria below.
Location: UCSF Fresno — Clovis, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (242 Sites)
Showing the first 25 of 242 sites.
- UCSF Fresno — Clovis, California
- UCLA — Santa Monica, California
- Yale University School Of Medicine — New Haven, Connecticut
- Medical Oncology Hematology Consultants, PA — Newark, Delaware
- Memorial Healthcare System — Hollywood, Florida
- Moffitt Cancer Center — Tampa, Florida
- Winship Cancer Institute Emory University — Atlanta, Georgia
- City of Hope Cancer Center — Newnan, Georgia
- Kootenai Health — Coeur d'Alene, Idaho
- Loyola University Medical Center — Maywood, Illinois
- University of Iowa Health Care — Waukee, Iowa
- Norton Cancer Institute — Louisville, Kentucky
- Our Lady of the Lake Hospital — Baton Rouge, Louisiana
- Luminis Health Center for Cancer and Blood Disorders — Annapolis, Maryland
- University of Maryland School of Medicine — Baltimore, Maryland
- The Sidney Kimmel Comprehensive Cancer Center at John Hopkins — Baltimore, Maryland
- University of Michigan — Ann Arbor, Michigan
- Henry Ford Cancer Institute — Detroit, Michigan
- Henry Ford Health Providence Southfield Hospital — Southfield, Michigan
- University Of Minnesota — Minneapolis, Minnesota
- Mayo Clinic Rochester — Rochester, Minnesota
- Regions Hospital — Saint Paul, Minnesota
- University of Nebraska — Omaha, Nebraska
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.